腹膜胶质瘤病临床病理分析
作者: |
1冯会敏,
2孙洋,
3杨迷玲,
4廉世萍,
5吴焕文
1 衡水市第二人民医院病理科,河北 衡水 053000 2 中国医学科学院阜外医院试验诊断中心,北京 100037 3 郑州市人民医院病理科,郑州 450000 4 呼伦贝尔市中蒙医院病理科,内蒙古 呼伦贝尔 021000 5 中国医学科学院北京协和医院病理科,北京 100032 |
通讯: |
吴焕文
Email: whw14093@163.com |
DOI: | 10.3978/j.issn.2095-6959.2017.10.019 |
摘要
目的:探讨腹膜胶质瘤病(gliomatosis peritonei,GP)的临床病理特征。方法:观察和分析15例GP患者的临床病理学特征,并复习相关文献。结果:15例GP患者,年龄6~28(中位22)岁;合并卵巢未成熟畸胎瘤12例,成熟畸胎瘤2例,混合性生殖细胞瘤1例;15例中8例与原发瘤同时发现,7例二次手术时发现。随访5~148个月,至随访终点,15例中有4例复发或进展;GP是否复发或进展与原发瘤破裂/粘连有显著相关性(χ2=2.47,P=0.03),与患者年龄、化疗与否、是否妊娠、淋巴结有无转移、原发肿瘤大小、原发肿瘤是否成熟、原发瘤未成熟成分分级、GP自身大小均无统计学意义(P>0.05)。结论:GP非常罕见,主要发生于卵巢未成熟畸胎瘤,有着独特的临床病理学特征,当原发瘤破裂/粘连时,复发或进展概率增高,须长期随访。
关键词:
腹膜胶质瘤病
卵巢畸胎瘤
临床病理特征
预后
Clinicopathologic features of gliomatosis peritonei
CorrespondingAuthor: WU Huanwen Email: whw14093@163.com
DOI: 10.3978/j.issn.2095-6959.2017.10.019
Abstract
Objective: To elucidate the pathological and clinical features of gliomatosis peritonei (GP). Methods: Fifteen cases of GP were obtained from Peking Union Medical College Hospital (PUMCH). The clinical and pathological findings were analyzed with a review of literature. Results: Fifteen patients aged 6–28 (median, 22) years. The primary ovarian tumors consisted of immature teratoma (n=12) and mature teratoma (n=2). GP was discovered with the primary tumor in 8 patients and at a secondary surgery in 7 patients. Follow-up data were available for 15 patients with a follow-up time of 5–148 months. Recurrence or progression were found in 4 of 15 patients (26.7%). We found that recurrence or progression was correlated with primary tumor rupture or adhesion (χ2=2.47, P=0.03), but not correlated with age, chemotherapy, pregnancy, lymphatic metastasis, primary tumor size, primary tumor maturity, grade of primary tumor (P>0.05). Conclusion: GP is rare, and often associated with ovarian teratoma. Owing to the risk of recurrence and malignant transformation of GP, a long-term follow-up is necessary, especially for those with primary tumor rupture or adhesion.
Keywords:
gliomatosis peritonei
ovarian teratoma
clinicopathologic features
Prognosis